Citigroup
NDRA icon

Citigroup’s ENDRA Life Sciences NDRA Stock Holding History

Citigroup’s Portfolio NDRA Stock Details NDRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$5 – 6236
2025
Q4 		$5 Buy
+1
New +$6 ﹤0.01% 5862
2022
Q3 		– Sell
-1
Closed -$7K – 6160
2022
Q2 		$7K Buy
+1
New +$8.94K ﹤0.01% 5502

Other funds holding NDRA

ACM
Altium Capital Management New York $42M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.99% 1-Year Est. Return

Citigroup's NDRA Position: Q1 2026 in Review

Citigroup sold out of ENDRA Life Sciences (NDRA) in Q1 2026, closing a stake of 1 share — an estimated $5 sold.

Citigroup first reported a position in NDRA in Q2 2022 and held it in 2 quarters. The position peaked at $7K in Q2 2022. 8 funds tracked by Wall St. Rank hold NDRA as of Q1 2026.

  • Citigroup reported no remaining ENDRA Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 1 ENDRA Life Sciences share in Q1 2026, an estimated $5.
  • Citigroup first reported a position in ENDRA Life Sciences in Q2 2022 and held it in 2 quarters.
  • Citigroup's ENDRA Life Sciences position peaked at $7K in Q2 2022.
  • 8 funds tracked by Wall St. Rank held ENDRA Life Sciences as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.